Therapeutic Targeting of VEGF And/or TGF-β to Enhance Anti-PD-(L)1 Therapy: The Evidence from Clinical Trials

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Aug 12

PMID 35957885

Authors

Linwei Li

Qinglian Wen

Ruilin Ding

Affiliations

Soon will be listed here.

Abstract

Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-β pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-β therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-β therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.

Citing Articles

IL-1β and associated molecules as prognostic biomarkers linked with immune cell infiltration in colorectal cancer: an integrated statistical and machine learning approach.

Sahoo K, Sundararajan V Discov Oncol. 2025; 16(1):252.

PMID: 40019680 PMC: 11871282. DOI: 10.1007/s12672-025-01989-3.

Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication.

Wang H, Wang T, Yan S, Tang J, Zhang Y, Wang L Mol Cancer. 2024; 23(1):268.

PMID: 39614288 PMC: 11607834. DOI: 10.1186/s12943-024-02183-9.

Editorial for the Special Issue "Angiogenic Growth Factors in Tumor Development: Beyond New Blood Vessels Formation".

Palumbo C, Albonici L Biomedicines. 2024; 12(11).

PMID: 39595106 PMC: 11591997. DOI: 10.3390/biomedicines12112541.

Chemoresistance and the tumor microenvironment: the critical role of cell-cell communication.

Wilczynski B, Dabrowska A, Kulbacka J, Baczynska D Cell Commun Signal. 2024; 22(1):486.

PMID: 39390572 PMC: 11468187. DOI: 10.1186/s12964-024-01857-7.

Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in....

Trieu V, Maida A, Qazi S Cancers (Basel). 2024; 16(6).

PMID: 38539537 PMC: 10968971. DOI: 10.3390/cancers16061202.

References

Wu F, Xu P, Chow A, Man S, Kruger J, Khan K . Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer. 2018; 120(2):196-206. PMC: 6342972. DOI: 10.1038/s41416-018-0297-1. View

Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H . Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer. 2021; 160:111-117. DOI: 10.1016/j.lungcan.2021.08.006. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Holderfield M, Hughes C . Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res. 2008; 102(6):637-52. DOI: 10.1161/CIRCRESAHA.107.167171. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Xie L, Xu J, Sun X, Guo W, Gu J, Liu K . Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer. 2020; 8(1). PMC: 7223462. DOI: 10.1136/jitc-2020-000798. View

Choueiri T, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018; 19(4):451-460. DOI: 10.1016/S1470-2045(18)30107-4. View

10.

Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J . Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2020; 27(4):1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571. View

11.

de Almeida P, Mak J, Hernandez G, Jesudason R, Herault A, Javinal V . Anti-VEGF Treatment Enhances CD8 T-cell Antitumor Activity by Amplifying Hypoxia. Cancer Immunol Res. 2020; 8(6):806-818. DOI: 10.1158/2326-6066.CIR-19-0360. View

12.

Roncarolo M, Levings M, Traversari C . Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 2001; 193(2):F5-9. PMC: 2193342. DOI: 10.1084/jem.193.2.f5. View

13.

Strauss J, Gatti-Mays M, Cho B, Hill A, Salas S, McClay E . Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020; 8(2). PMC: 7745517. DOI: 10.1136/jitc-2020-001395. View

14.

Bang Y, Golan T, Dahan L, Fu S, Moreno V, Park K . Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020; 137:272-284. DOI: 10.1016/j.ejca.2020.06.007. View

15.

Cho B, Daste A, Ravaud A, Salas S, Isambert N, McClay E . Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020; 8(2). PMC: 7342865. DOI: 10.1136/jitc-2020-000664. View

16.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

17.

Courau T, Nehar-Belaid D, Florez L, Levacher B, Vazquez T, Brimaud F . TGF- and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016; 1(9):e85974. PMC: 5033816. DOI: 10.1172/jci.insight.85974. View

18.

Esebanmen G, Langridge W . The role of TGF-beta signaling in dendritic cell tolerance. Immunol Res. 2017; 65(5):987-994. DOI: 10.1007/s12026-017-8944-9. View

19.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J . Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100(7):1111-9. PMC: 2670006. DOI: 10.1038/sj.bjc.6604965. View

20.

Khan K, Kerbel R . Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018; 15(5):310-324. DOI: 10.1038/nrclinonc.2018.9. View